Arbutus Expands HBV Pipeline
By GlobeNewswire, May 03, 2016, 04:30:00 PM EDT
Technology License Enables the Development of RNaseH Inhibitors for HBV
VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announced a licensing and research collaboration agreement with the Saint Louis University Liver Center to develop Ribunuclease H (RNaseH) inhibitors.
"This collaboration allows us to further expand our pipeline and add another program focusing on a novel aspect of the HBV viral lifecycle. This is consistent with our strategy of having multiple assets under one roof to achieve efficient screening and selection of promising product candidates for advancement into clinical combination studies," said Dr. Mark J. Murray
, Arbutus' President and CEO. "RNaseH is a component of the viral polymerase and crucial to HBV replication. We believe that an RNaseH inhibitor could complement other direct antiviral HBV products by further crippling the viral replication process, which we believe is going to be a critical component in achieving a cure for chronic HBV." 作者: StephenW 时间: 2016-5-4 14:58